Compass Financial Management’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Compass Financial Management’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.5K	Buy	+756	New	+$26.3K	﹤0.01%	801

Other funds holding FTXH

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Compass Financial Management's FTXH Position: Q2 2026 in Review

Compass Financial Management opened a new position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q2 2026: 756 shares worth $29.5K. The stake represents ﹤0.01% of the portfolio and ranks #801 among its holdings.

31 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

Compass Financial Management held 756 shares of First Trust Nasdaq Pharmaceuticals ETF worth $29.5K as of Q2 2026.
First Trust Nasdaq Pharmaceuticals ETF was a new Compass Financial Management position in Q2 2026.
First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Compass Financial Management's portfolio in Q2 2026, its #801 holding.
31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Compass Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.